

# *CURRICULUM VITAE*

**Hernando Zegarra, MD**

**OFFICE ADDRESSES** Retina Associates of Cleveland, Inc.  
3401 Enterprise Parkway, Suite 300; Cleveland, Ohio 44122  
14601 Detroit Avenue, Suite 200; Cleveland, Ohio 44107  
15299 East Bagley Road, Suite 200; Cleveland, Ohio 44130  
5390 Belmont Avenue; Youngstown, Ohio 44505  
1 Park West, Suite 150; Akron, Ohio 44320  
3919 East Market Street; Warren, Ohio 44484  
9485 Mentor Avenue, Suite 211; Mentor, Ohio 44060  
6100 South Broadway Avenue, Suite 200; Lorain, Ohio 44052

**TELEPHONE** 216-831-5700

## **EDUCATION**

*Medical School* Cayetano Heredia University  
Lima, Peru  
1968, MD

## **POSTGRADUATE TRAINING**

*Internship* Loayza Hospital  
*(Peru)* Lima, Peru  
April 1967 to March 1968

*Residency* Ophthalmology  
*(Peru)* Cayetano Heredia University  
Lima, Peru  
April 1968 to March 1969

*Internship* Rotating internship  
*(United States)* Grasslands Hospital (now Westchester Medical Center)  
Valhalla, New York  
July 1969 to June 1970

*Fellowship* Retinal fluorescein angiography  
Cleveland Clinic Foundation, Department of Ophthalmology  
Cleveland, Ohio  
July 1970 to June 1971

*Residency*  
*(United States)* Ophthalmology  
Cleveland Clinic Foundation, Department of Ophthalmology  
Cleveland, Ohio  
July 1971 to June 1974

*Fellowship* Ophthalmic and Retinal Diseases and Surgery  
Devers Eye Clinic of Good Samaritan Hospital  
Portland, Oregon  
July 1974 to September 1975

## LICENSURE AND BOARD CERTIFICATION

Licensed to practice medicine in Ohio

Diplomate, American Board of Ophthalmology, 1977

## PROFESSIONAL POSITIONS

Retina Associates of Cleveland, 1989-

Practice limited to retinal diseases and surgery. Associates: Lawrence J. Singerman, MD; Michael A. Novak, MD; Z. Nicholas Zakov, MD; Scott D. Pendergast, MD; David G. Miller, MD; Joseph M. Coney, MD; Jerome P. Schartman, MD

Director, Electrophysiology and Fluorescein Angiography Laboratories, October 1975 to December 1988

Cleveland Clinic Foundation, Department of Ophthalmology, Retina Service  
Cleveland, Ohio

## HONORS AND AWARDS

Best Doctors in America, 2011

Best Doctors in Cleveland, *Cleveland Magazine*, 2011

## MEMBERSHIPS

American Academy of Ophthalmology  
American Medical Association  
American Society of Retinal Specialists (formerly the Vitreous Society)  
Association for Research in Vision and Ophthalmology  
Cleveland Academy of Medicine  
Cleveland Ophthalmological Society  
Colombian Ophthalmology Society (Honorary Member)  
Diabetes Association of Greater Cleveland  
Latin American Group on Ocular Angiography and Photocoagulation  
Ohio State Medical Association

Pan-American Ophthalmological Society  
Peruvian Ophthalmological Society  
Peruvian-American Medical Society  
Retina Society

## RESEARCH ACTIVITIES

### *NIH-funded Grants*

*Central Vein Occlusion Study*

Co-investigator, 1988 – 1993

*Macular Photocoagulation Studies*

Co-investigator, 1989 – 1993

*Endophthalmitis Vitrectomy Study*

Co-investigator, 1989 – 1994

*Central Vein Occlusion Study (CVOS) Electrophysiology Ancillary Study*

Principal investigator, 1990 – 1992

*Collaborative Ocular Melanoma Study*

Co-investigator, 1987 – 2003

*Epidemiology of Diabetes Interventions and Complications Trial (EDIC), National Institutes of Health Grant*

Co-investigator, 1994 –

*Complications of Age-related Macular Degeneration Prevention Trial (CAPT)*

Co-investigator, 1999 – 2006

*Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study*

Co-investigator, 2004 – 2009

*Age-Related Eye Disease Study 2 (AREDS2)*

Co-investigator, 2006 –

*Comparison of age-related macular degeneration treatments trials: Lucentis-Avastin trial (CATT)*

Co-investigator, 2008-

### *Other National Clinical Trials*

*Visudyne photodynamic therapy treatment of neovascular age-related macular degeneration (multiple studies)*

Co-investigator, 1997 – 2006

*Protein Kinase C  $\beta$  inhibitor ruboxistaurin treatment for diabetic macular edema study and diabetic retinopathy (multiple studies)*

Co-investigator, 1998 –

*Evaluation of anecortave acetate in patients with exudative age-related macular degeneration (multiple studies)*

Co-investigator, 1999 – 2008

*Oculex Study: A Phase 2 randomized, multicenter, dose-ranging, controlled, parallel-group trial to assess the safety and effectiveness of dexamethasone posterior segment drug delivery system (DEX PS DDS<sup>®</sup>) in the treatment of persistent macular edema*

Co-investigator, 2001 – 2003

*Pegaptanib sodium (Macugen) in patients with exudative age-related macular degeneration (multiple studies)*

Co-investigator, 2001 – 2010

*Ranibizumab (Lucentis) treatment in subjects with neovascular age-related macular degeneration (multiple studies)*

Co-investigator, 2003 – 2007

*A study of ranibizumab injection in subjects with clinically significant with macular edema center involvement secondary to diabetes mellitus (RIDE)*

Co-investigator, 2007 –

*The Implantable Miniature Telescope (IMT<sup>™</sup>) in patients with central vision impairment associated with age-related macular degeneration or Stargardt's macular dystrophy*

Co-investigator, 2003 – 2005

*A randomized, double-masked, placebo-controlled, parallel group, multicenter, dose-ranging study of denufosol tetrasodium (INS37217) intravitreal injection in subjects with rhegmatogenous retinal detachment*

Co-investigator, 2004 – 2005

*Protocol A43221001: A Phase 1 / 2 randomized, masked, placebo-controlled, single and multiple-dose, sequential dose escalation study of the safety and efficacy of AG-013958 in subjects with subfoveal choroidal neovascularization associated with age-related macular degeneration*

Co-investigator, 2004 – 2006

*An open label study for the evaluation of tolerability of four dose levels of Cand5 administered by single intravitreal injection in patients with wet age-related macular degeneration*

Co-investigator, 2005 – 2007

*A Phase II, dose ranging, open-labeled, multi-center study to evaluate the safety and efficacy of combretastatin A4 phosphate for treating subfoveal choroidal neovascularization in subjects with pathologic myopia*

Co-investigator, 2005 – 2006

*Cand5 Anti-VEGF RNAi Evaluation (CARE): Dose comparison of Cand5 for subfoveal choroidal neovascularization associated with wet age-related macular degeneration.*

Co-investigator, 2005 – 2007

*Natural history study of macular telangiectasia (MacTel)*

Co-investigator, 2005-

*RNAi Assessment of Cand5 in Diabetic Macular Edema (RACE)*

Co-investigator, 2005 – 2007

*A 3-year, Phase III, multicenter, masked, randomized, sham-controlled trial to assess the safety and efficacy of 700 µg and 350 µg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in the treatment of patients with diabetic macular edema.*

Co-investigator, 2005 – 2007

*A 6-month, Phase III, multicenter, masked, randomized, sham-controlled trial (with 6-month open-label extension) to assess the safety and efficacy of 700 µg and 350 µg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in the treatment of patients with macular edema following branch retinal vein occlusion or central retinal vein occlusion*

Co-investigator, 2005 – 2007

*Phase II randomized, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of geographic atrophy in age-related macular degeneration (Sirion Therapeutics)*

Co-investigator, 2007 – 2010

*Small Interfering RNA In Macular Degeneration Study (SIRIUS): A 2 year, multicenter, randomized, controlled, masked, dose-finding trial to assess the safety and efficacy of multiple intravitreal injections of AGN211745 in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration*

Co-investigator, 2007 – 2008

*Age-related Macular Degeneration: Detection of Onset of new Choroidal neovascularization (AMD DOC) study comparing preferential hyperacuity perimetry (PHP) with supervised Amsler grid in detecting AMD for earlier treatment in high-risk fellow eyes (Johns Hopkins)*

Co-investigator, 2007 – 2009

*OMEGA: A randomized, double-masked, dose-ranging, multi-center, phase II study comparing the safety and efficacy of OT-551 with placebo to treat geographic atrophy associated with age-related macular degeneration*

Co-investigator, 2007 – 2009

*COBALT: COmbining Bevasiranib And Lucentis Therapy. A phase III, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis®, compared with Lucentis® monotherapy every 4 weeks in patients with exudative age-related macular degeneration (AMD)*

Co-investigator, 2007 – 2008

*A study of ranibizumab injection in subjects with clinically significant with macular edema center involvement secondary to diabetes mellitus (RIDE)*

Co-investigator, 2007 –

*A masked, multicenter, randomized, controlled trial to assess the safety and efficacy of 700 µg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of subjects with diffuse diabetic macular edema*

Co-investigator, 2007 – 2009

*Phase 1, single ascending dose trial to establish the safety, tolerability, and pharmacokinetic profile of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) monotherapy and of E10030 given in combination with Lucentis 0.3mg/eye in subjects with neovascular AMD*

Co-investigator, 2007-

*A multicenter, randomized, placebo-controlled, double-masked, parallel group, dose-ranging clinical trial of intravitreal microplasmin in patients undergoing surgical vitrectomy: The MIVI III (Microplasmin for Vitreous Injection III) Trial*

Co-investigator, 2007 – 2009

*Phase 1, single ascending dose and parallel group trial to establish the safety, tolerability, and pharmacokinetic profile of multiple intravitreal injections of Volociximab ( $\alpha 5\beta 1$  integrin antagonist) as monotherapy or given in combination with Lucentis 0.5mg/eye in subjects with neovascular AMD (Ophthotech 3000)*

Co-investigator, 2008 –

*Phase 2, randomized, double-masked, placebo-controlled, dose-ranging clinical study to assess the safety and efficacy of subconjunctival injections of sirolimus in patients with diabetic macular edema secondary to diabetic retinopathy*

Co-investigator, 2008 – 2010

*Natural History of Geographic Atrophy Progression (GAP) Study (Alcon)*

Co-investigator, 2008 – 2009

*Geographic Atrophy Treatment Evaluation (GATE) Study (Alcon)*

Co-investigator, 2009 –

*Phase II, randomized, double-masked, placebo- controlled, add-on study to assess the efficacy of oral aliskiren 300 mg one daily for diabetic macular edema*

Co-investigator, 2009 –

*Impact of Lucentis on psychological morbidity in patients with macular edema and neovascularization secondary to retinal vein occlusion*

Co-investigator, 2009 –

*Phase 2, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) given in combination with Lucentis® in subjects with neovascular age-related macular degeneration*

Co-investigator, 2010 –

*Phase 2b dose-ranging study of pazopanib eye drops versus ranibizumab intravitreal injections for the treatment of neovascular age-related macular degeneration*

Co-investigator, 2010 –

## SELECTED PRESENTATIONS AT LOCAL, NATIONAL, AND INTERNATIONAL MEETINGS AND SYMPOSIA

- 1) Basics in fluorescein angiography. 2) Diabetic retinopathy. Cayetano Heredia University. Lima, Peru. March 1976.
- A perspective on the diagnosis and management of diabetic retinopathy. Endocrinology Postgraduate Course, Cleveland Clinic Foundation. Cleveland, Ohio. February 1976.
- Fluorescein angiography course, Part I (Course Director). Cleveland Clinic Foundation. Cleveland, Ohio. April 8, 1976.
- Fluorescein angiography course, Part II (Course Director). Cleveland Clinic Foundation, Cleveland, Ohio. November 3, 1976.
- Management of diabetic retinopathy. Perspectives in Ophthalmology, Cleveland Clinic Foundation. Cleveland, Ohio. December 1976.
- Ocular vaso-occlusive disease. Department of Medicine, Cleveland Clinic Foundation. Cleveland, Ohio. September 16, 1977.
- Usher Syndrome. Retinitis Pigmentosa Foundation, Cleveland Chapter. September 18, 1977.
- Ocular manifestations of diabetes mellitus. Diagnosis and management of common problems in medical practice (Course for general practitioners). Cleveland Clinic Foundation. Cleveland, Ohio. May 5, 1977.
- Diabetic retinopathy. Department of Endocrinology, Cleveland Clinic Foundation. Cleveland, Ohio. February 17, 1978.
- Leukemic retinopathy. American Medical Association. St. Louis, Missouri. June 21, 1978.

11. Ocular complications in cardiac surgery. Peruvian-American Medical Society. Sandom, Puerto Rico. August 2, 1978.
12. Natural course of central retinal vein occlusion. American Academy of Ophthalmology. October 24, 1978.
13. Natural course of central retinal vein occlusion. Retina Society. Houston, Texas. November 10-11, 1978.
14. Ocular electrophysiology: clinical applications. Perspectives in ophthalmology, Postgraduate course, Cleveland Clinic Foundation. Cleveland, Ohio. December 2, 1978.
15. Natural course of central retinal vein occlusion. Pan-American Association of Ophthalmology. Miami, Florida. February 25 to March 2, 1979.
16. Retinal manifestations of rheumatic disease. Department of Rheumatology, Cleveland Clinic Foundation. Cleveland, Ohio. May 21, 1979.
17. Retinal Angiography Course. Ophthalmic Photographers Society, Eastern Regional Fourth Meeting. Erie, Pennsylvania, June 16, 1979.
18. Retinal Vascular Diseases Course. First International Congress of Surgery. Lima, Peru, July 2-5, 1979.
19. Diabetic retinopathy. Department of Endocrinology, Cleveland Clinic Foundation. Cleveland, Ohio. September 28, 1979.
20. Retinal photocoagulation. Perspectives in ophthalmology, Cleveland Clinic Foundation. Cleveland, Ohio. December 6-7, 1979.
21. 1) Photocoagulation in diabetic retinopathy. 2) Retinal detachment — surgical technique. 3) Round Table on retinal disease — Case Presentation. Peruvian-American Medical Society. Lima, Peru. December 16-22, 1979
22. Fluorescein angiography in choroidal disease. Peruvian Ophthalmological Society. Lima, Peru. December 28, 1979.
23. Ocular manifestations of diabetes mellitus. Hospital de Policia. Lima, Peru. January 4, 1980.
24. 1) Complications of cataract surgery. 2) Retinal detachment. Universidad Federico Villareal. Lima, Peru. January 4, 1980.
25. Ocular manifestations of diabetes mellitus. Hospital de la Fuerza Aerea. Lima, Peru. January 10, 1980.

26. Natural course of central retinal vein occlusion. Erie Eye Clinic. Erie, Pennsylvania. April 8-9, 1980.
27. Partial central retinal vein occlusion. 2) Photocoagulation in branch retinal vein occlusion. Retina Society. Philadelphia, Pennsylvania. October 10-11, 1980.
28. Retinal detachment: diagnosis and classification. Peruvian-American Medical Society. Spain. November 22-30, 1980.
29. Partial central retinal vein occlusion. Association for Research in Vision and Ophthalmology. Sarasota, Florida. April 27-May 1, 1981.
30. Common retinopathies. Veterans Administration Hospital. Brecksville, Ohio. June 19, 1981.
31. Symposium on Complications of Diabetes mellitus. Peruvian-American Medical Society. Bal Harbour, Florida. November 24-28, 1981.
32. Fluorescein angiography and laser photocoagulation. Guest of Honor, Fundacion Oftalmologica Nacional of Bogota, Colombia. Bogota, Colombia. December 4-6, 1981.
33. Fluorescein angiography in neuro-ophthalmology. Latin-American Course and Symposium of Neuro-Ophthalmology. Lima, Peru. December 6-11, 1981.
34. 1) Fluorescein angiography in diabetic retinopathy. 2) Branch vein occlusion, natural history and management. 3) Central retinal vein occlusion, types and management. Peruvian-American Medical Society. Lima, Peru. July 5-9, 1982.
35. 1) The role of laser therapy in the management of diabetic retinopathy. 2) Ocular manifestations of diabetes. Cleveland Clinic Foundation Diabetes Update Course. Cleveland, Ohio. October 27-28, 1982.
36. Management of central retinal vein occlusion. Cleveland Ophthalmological Society. Cleveland, Ohio. April 12, 1983.
37. Improvement in retinal circulation after extracranial-intracranial bypass surgery for carotid occlusive disease. Association for Research in Vision and Ophthalmology Annual Meeting. Sarasota, Florida. May 1-5, 1983.
38. A practical course in laser eye surgery: venous occlusive disease. St. Francis General Hospital. Pittsburgh, Pennsylvania. June 4, 1983.
39. 1) Retinal vein occlusion. 2) Management of the diabetic patient. 3) Course on macular diseases. XIV Pan-American Congress of Ophthalmology. Lima, Peru. July 3-8, 1983.
40. Decreased vision: diagnosis for the non-ophthalmologist. Peruvian-American Medical Society. San Francisco, California. September 13-17, 1983.

41. 1) New concepts in the diagnosis and treatment of retinal venous occlusive disease. 2) Round table on different modalities of laser therapy. XII Argentinean National Congress of Ophthalmology. Buenos Aires, Argentina. September 18-23, 1983.
42. 1) Clinicophysiological evaluation of visual dysfunction. 2) Current concepts in venous occlusive disease. 3) Round table on photocoagulation. Venezuelan National Congress of Ophthalmology. Barquisimeto, Venezuela. November 20-24, 1983.
43. Role of photocoagulation in retinal venous occlusions. Lasers in ophthalmology, postgraduate course. Cleveland Clinic Foundation. Cleveland, Ohio. December 2-3, 1983.
44. Preretinal neovascularization secondary to intraocular inflammation. Cleveland Ophthalmological Society. Cleveland, Ohio. May 2, 1984.
45. First Congress, Aristides de Athayde Eye Foundation, Ophthalmology 1984. Curitiba, Parana, Brazil. June 20-23, 1984.
46. Lasers in ophthalmology. Peruvian-American Medical Society. Arequipa, Peru. July 2-5, 1984.
47. Photocoagulation of intraocular tumors. International Congress on Intraocular Tumors. Lima, Peru. July 6, 1984.
48. Symposium on diabetic retinopathy. Lima, Peru. July 6, 1984.
49. Intraocular lenses on diabetic patients. Retina Society Annual Meeting. Detroit, Michigan. September 13-16, 1984.
50. 1) Evaluation of retinal ischemia by fluorescein angiography. 2) Round table on diabetic retinopathy (coordinator). 3) Intraocular lenses in diabetic patients. Latin-American Forum — Angiography and Photocoagulation. Buenos Aires, Argentina. October 24-26, 1984.
51. Complications in ophthalmology: complications of intraocular lenses in diabetic patients. Postgraduate course, Cleveland Clinic Foundation. Cleveland, Ohio. November 30 to December 1, 1984.
52. The use of the Lincoff balloon in retinal detachment surgery. Cleveland Ophthalmological Society. Cleveland, Ohio. April 9, 1985.
53. Retinal vascular diseases. Postgraduate course, XV Pan-American Congress of Ophthalmology. New Orleans, Louisiana. April 21, 1985.
54. The management of retinal venous occlusive disease. Postgraduate course, American Academy of Ophthalmology. San Francisco, California. October 3, 1985.

55. Management of retinal vascular occlusion. Buffalo Ophthalmological Society. Buffalo, New York. October 17, 1985.
56. Vascular occlusive disease. Erie County Medical Center case presentation. Buffalo, New York. October 17, 1985.
57. Retinal manifestations of carotid occlusive disease. Peripheral Vascular Disease Conference, Cleveland Clinic Foundation. Cleveland, Ohio. January 29, 1986.
58. Ophthalmic dye lasers: A. Applications of retinal clinical trials. B. The use of different wavelengths. Joint Ophthalmology Conference of Case Western Reserve University School of Medicine and Cleveland Clinic Foundation. Cleveland, Ohio. February 15, 1986.
59. Common retinal disorders: recognition and management. Primary Care Conference, Cleveland Clinic Foundation. Cleveland, Ohio. February 25, 1986.
60. Dye lasers — use of dye lasers in ophthalmology: management of neovascularization secondary to intraocular inflammation. Latin American Group of Angiography and Photocoagulation. Belo Horizonte, Brazil. Angiography Workshop (organizer). April 18-19, 1986.
61. Temporary closure of retinal breaks. Hilton Rocha Institute Meeting. Belo Horizonte, Brazil. April 20-21, 1986.
62. Treatment of macular edema secondary to partial central retinal vein occlusion. Ohio Ophthalmological Society. Columbus, Ohio June 7-8, 1986.
63. Temporary closure of retinal breaks — new approach for retinal detachment repair. Dedicatory Symposium, Department of Ophthalmology, Cleveland Clinic Foundation. Cleveland, Ohio. June 14, 1986.
64. Retinal angiography: basic interpretation and current use of lasers in the treatment of eye disorders. Ohio Optometric Association. Huron, Ohio. October 8-9, 1986.
65. New techniques for retinal detachments. Peruvian Congress of Ophthalmology. Lima, Peru. November 2-7, 1986.
66. Cataract surgery and intraocular lenses in diabetic patients. Vitreous Society Meeting. Palm Springs, California. December 3-6, 1986.
67. Retinal venous occlusive disease — current management and treatment. Pan American Association of Ophthalmology. Santo Domingo, Dominican Republic. April 5-7, 1987.
68. Comparison of pneumatic retinopexy with alternative surgical techniques. American Academy of Ophthalmology Annual Meeting. Dallas, Texas. November 8-12, 1987.

69. 1) Persistent macular detachment after pneumatic retinopexy. 2) Simultaneous gas-fluid exchange in nonvitrectomized eyes. Vitreous Society Meeting. St. Thomas, Virgin Islands. December 2-6, 1987.
70. 1) Complications of CRNVM treatment. 2) Laser photocoagulation for retinal tears and lattice degeneration. 3) Macular edema secondary to CRVO. Retina Research and Development Foundation Mid-Winter Course and Fluorescein Angiography Workshop. St. Louis, Missouri. February 5-6, 1988.
71. A new approach for the repair of retinal detachment associated with retinoschisis. The Retina Society Meeting. Philadelphia, Pennsylvania. June 16-18, 1988.
72. Acute bilateral maculopathies. 2) Coordinator, Round Table on retinal vascular disease. 3) Retinal vascular disease: current therapy. Latin American Group of Angiography and Photocoagulation. Caracas, Venezuela. June 19-25, 1988.
73. Reoperation following pneumatic retinopexy. 2) CCF experience with pneumatic retinopexy. Pneumatic Retinopexy Symposium. San Diego, California. August 5-6, 1988.
74. 1) Overview of macular degeneration. 2) An alternative technique to scleral buckling surgery: pneumatic retinopexy. Update on Vitreoretinal Disease. Christ Hospital. September 10, 1988.
75. Clinical applications of electrophysiology. Grand Rounds St. Luke's Hospital. Cleveland, Ohio. February 3, 1989.
76. Chronic macular detachment following otherwise successful pneumatic retinopexy (Ambler JS, Zegarra H, Meyers SM). Combined Meeting of the Retina Society and Macula Society. Boston, Massachusetts. June 21-24, 1989.
77. Pneumatic retinopexy for retinal redetachments after buckling surgery (Zegarra H, Parker C, Meyers S). Aegean Retina. Crete, Greece. July 10-14, 1989.
78. Current indications and limitations of pneumatic retinopexy. Ohio Ophthalmological Society Meeting. Cleveland, Ohio. June 2-4, 1989.
79. 1) Update on laser photocoagulation for retinal vein occlusion. 2) Current status of retinal venous occlusive disease (central retinal vein occlusion). 3) Acute maculopathies. 4) Management of proliferative diabetic retinopathy. 5) Free paper: Failure and reoperation following pneumatic retinopexy. Pan-American Ophthalmological Society Meeting. Rio de Janeiro, Brazil. September 3-6, 1989.
80. Update on pneumatic retinopexy experience at the Cleveland Clinic. Pneumatic Retinopexy Symposium. Tampa, Florida. October 6-7, 1989.
81. 1) Pneumatic retinopexy, technique, indications, and limitations. 2) Management of retinal branch vein occlusion. 3) Clinical applications of dye laser. 4) Ischemia in

- central retinal vein occlusion. 5) Management of retinoschisis complicated with retinal detachment. Guest lecturer, Decentro Oftalmologico Campinas. October 20-21, 1989.
82. Reoperations following pneumatic retinopexy (Ambler J, Meyers S, Zegarra H). American Academy of Ophthalmology Annual Meeting. New Orleans, Louisiana. October 29-November 2, 1989.
  83. Alternative techniques to scleral buckling surgery. Case Western Reserve University Grand Rounds. Cleveland, Ohio. December 6, 1989.
  84. What's new in vitreoretinal diseases (in Spanish). Senior Instructor, American Academy of Ophthalmology Annual Meeting. Anaheim, California. October 13-17, 1991.
  85. Ophthalmological Workshop. Ohio Academy of Family Physicians. January 11, 1992.
  86. Acquired retinopathies simulating retinal dystrophies. Cleveland Ophthalmological Society. April 14, 1992.
  87. Evaluation of retinal ischemia: clinical, angiographic, and electrophysiological findings; Review of interesting fluorescein cases (coordinator). Latin American Group for Fluorescein Angiography and Laser. Cancun, Mexico. July 16-18, 1992.
  88. 1) What's new in vitreoretinal diseases (Panelist). 2) Branch and central vein occlusion workshop (Instructor). 3) Discussant of two papers on choroidal neovascularization. American Academy of Ophthalmology Annual Meeting. Dallas, Texas. November 8-12, 1992.
  89. 1) Treatment of subfoveal choroidal neovascularization. 2) Pneumatic retinopexy. 3) Current indications and management of retinal vein occlusion. The Northwest Mexican Ophthalmology Society Annual Meeting. Tucson, Arizona; May 1993.
  90. Edema and retinal ischemia and retinal vascular occlusions. The Nineteenth Pan-American Congress of Ophthalmology. Caracas, Venezuela; July 1993.
  91. 1) Symposium in retinal diseases. 2) Conference on retinitis pigmentosa and vitamin A. Fifteenth Peruvian Symposium of Ophthalmology. Lima, Peru. September 1994.
  92. Symposium on indocyanine green angiography. Latin American Group of Angiography and Laser Photocoagulation. Santiago, Chile. October 1994.
  93. What's new in vitreoretinal diseases and surgery (Panelist). American Academy of Ophthalmology and the Pan-American Association of Ophthalmology. San Francisco, California. October 1994.
  94. 1) What's new in vitreoretinal diseases and surgery (Panelist). American Academy of Ophthalmology and the Pan-American Association of Ophthalmology. New Orleans, Louisiana. November 1998

95. 1) What's new in vitreoretinal diseases and surgery (Panelist). 2) Branch and central vein occlusion workshop (Instructor). 3) Manejo Práctico Actualizado de la Retina Diabética (Instructor). 4) Enfermedad Macular Tratable (Instructor). American Academy of Ophthalmology and the Pan-American Association of Ophthalmology. Orlando, Florida. October 24-27, 1999.
96. Management and prevention of retinal vascular disease. Ohio Optometric Association Zone 2 meeting. June 13, 2001.
97. Photodynamic therapy. Pan American Congress of Ophthalmology. Llao Llao, Argentina. July 23, 2001.
98. Management and prevention of retinal vascular disease. Optometric Retinal Update. Youngstown, Ohio. August 29, 2001.
99. 1) Manejo practico de la enfermedad retinal vascular. 2) Tratamiento de la neovascularizacion coroidea con terapia fotodinamica combinada con otras modalidades terapeuticas. National Congress of Ophthalmology. Lima, Peru. July 2-6, 2002.
100. Unilateral retinitis pigmentosa. Optometric Retinal Update. Westlake, Ohio. August 12, 2003.
101. Retinal case presentations and management. Optometric Continuing Medical Education. Vermilion, Ohio. December 11, 2003.
102. Unilateral retinitis pigmentosa. Optometric Retinal Update. Beachwood, Ohio. February 19, 2004.
103. Pigmented fundus lesions. Optometric Retinal Update. Westlake, Ohio. July 29, 2004.
104. Case review: retinal vascular and macular degenerative diseases. Optometric Retinal Update. Westlake, Ohio. August 11, 2005.
105. Newest information, research, and treatments for macular degeneration. Seminar on Nutrition and Macular Degeneration (joint presentation of Retina Associates of Cleveland and Macula Vision Research Foundation SupportSight). Middleburg Heights, Ohio. October 29, 2005.
106. Current management of retinal vein occlusion. Optometric Retinal Update. Westlake, Ohio. August 9, 2006.
107. Current management of retinal vein occlusion. Optometric Retinal Update. Youngstown, Ohio. September 25, 2006.
108. The role of anti-VEGF agents in retinal disorders. Optometric Retinal Update. Mentor, Ohio. October 25, 2006.

109. Anti-VEGF agents in retinal disorders. Optometric Retinal Update. Westlake, Ohio. July 17, 2007.
110. Central serous choroidopathy: current management and new therapies. Optometric Retinal Update. Beachwood, Ohio. February 21, 2008.
111. Photodynamic therapy with Visudyne in the treatment of central serous retinopathy. Optometric Retinal Update. Westlake, Ohio, July 15, 2008.
112. Central retinal vein occlusion: evolution in the diagnosis, management, and treatment. Optometric Retinal Update. Youngstown, Ohio. September 18, 2008.
113. Anti-VEGF therapy for central retinal vein occlusion. Retinal Update for Ophthalmologists. Youngstown, Ohio. November 20, 2008.
114. Retinal imaging (with DG Miller). Optometric Continuing Education Program and Open House. Lorain, Ohio. January 13, 2009.
115. Anti-VEGF therapy for central retinal vein occlusion. Retinal Update for Ophthalmologists. Youngstown, Ohio. March 18, 2009.
116. Anti-VEGF therapy for central retinal vein occlusion. Retinal Update for Ophthalmologists. Beachwood, Ohio. May 13, 2009.
117. Chloroquine retinopathy. Optometric Retinal Update. Westlake, Ohio, June 18, 2009.
118. Unilateral progressive hyperopia. Optometric Retinal Update Seminar. Beachwood, Ohio, March 25, 2010.
119. Long-term therapy of central retinal vein occlusion with anti-VEGF agents. Cleveland Ophthalmological Society. Cleveland, Ohio, October 12, 2010.
120. Co-moderator, Medical Retina Symposium. Speaker, 1) Long-term therapy of central retinal vein occlusion with anti-VEGF agents; 2) Photodynamic therapy in the treatment of central serous choroidopathy. Croatian Ophthalmological Society. Zagreb, Croatia, October 2010.
121. Eighteen years of recurrent central serous choroidopathy. North Coast Retina Symposium. Cole Eye Institute, Cleveland Clinic Foundation, May 13, 2011.

## **.PUBLICATIONS**

### ***Journal Articles***

1. Gutman FA, Zegarra H. Ocular complications in cardiac surgery. *Surg Clin North Am* 51:1095-1103, 1971.

2. Gutman FA, Zegarra H. The natural course of temporal retinal branch vein occlusion. *Trans Am Acad Ophthalmol Otolaryngol* 78:OP178-192, 1974.
3. Gutman FA, Zegarra H. Retinal detachment secondary to retinal branch vein occlusions. *Trans Am Acad Ophthalmol Otolaryngol* 81:491-496, 1976.
4. Gutman FA, Zegarra H, Zakov ZN. Retinal branch vein occlusion. *Perspect in Ophthalmol* 1(1), March 1977.
5. Zegarra H, Gutman FA. Ocular complications in cardiac surgery. *Perspect in Ophthalmol* 2(3), September 1978.
6. Zakov ZN, Rich LS, Zegarra H, Gutman FA. Differential diagnosis of preretinal neovascularization. *Perspect in Ophthalmol* 2(3), September 1978.
7. Zegarra H, Gutman FA, Conforto J. The natural course of central retinal vein occlusion. *Ophthalmology* 86:1931-1942, 1979.
8. Sakamoto DK, Zegarra H, Gutman FA, Zakov ZN. Silicone sponge implant in combination with episcleral implant for retinal detachment surgery. *Ophthalmic Surg* 11:712-718, 1980.
9. Gutman FA, Zegarra H, Rauer A, Zakov N. Photocoagulation in retinal branch vein occlusion. *Trans Am Ophthalmol Soc* 78:156-166, 1980.
10. Wilhelm JL, Zakov ZN, Weinstein MA, Berlin LA, Zegarra H, Gutman FA. Localization of suspected intraocular foreign bodies with a modified Delta 2020 scanner. *Ophthalmic Surgery* 12:633-641, 1981.
11. Gutman FA, Zegarra H, Rauer A, Zakov N. Photocoagulation in retinal branch vein occlusion. *Ann Ophthalmol* 13:1359-1363, 1981.
12. Lowder CY, Gutman FA, Zegarra H, Zakov ZN, Lowder J, Clough JD. Macular and paramacular detachment of the neurosensory retina associated with systemic diseases. *Trans Am Ophthalmol Soc* 79:347-370, 1981.
13. Dreyer WB Jr, Zegarra H, Zakov ZN, Gutman FA. Sympathetic ophthalmia: a case report. *Am J Ophthalmol* 92:816-823, 1981.
14. Zegarra H, Gutman FA, Zakov N, Carim M. Partial central retinal vein occlusion. *Invest Ophthalmol Vis Sci* 20 (Suppl):142, 1981.
15. Zegarra H, Gutman FA, Zakov N, Carim M. Partial occlusion of the central retinal vein. *Am J Ophthalmol* 96:330-337, 1983.
16. Aaby AA, Zegarra H. The tourniquet test in identifying diabetic retinopathy [letter] *JAMA* 250:1843-1844, 1983.

17. Gutman FA, Zegarra H. Macular edema secondary to occlusion of the retinal veins. *Surv Ophthalmol* 28 Suppl:462-470, 1984.
18. Ludwig IH, Zegarra H, Zakov ZN. The acute retinal necrosis syndrome: possible herpes simplex retinitis? *Ophthalmology* 91:169-174, 1984.
19. Standefer M, Little JR, Tomsak R, Furlan AJ, Zegarra H, Williams G. Improvement in the retinal circulation after superficial temporal to middle cerebral artery bypass. *Neurosurgery* 16:525-529, 1985.
20. Stern RM, Zakov ZN, Zegarra H, Gutman FA. Multiple recurrent serosanguineous retinal pigment epithelial detachments in black women. *Am J Ophthalmol* 100:560-569, 1985.
21. Meyers SM, Zegarra H, Nguyen DM, Skipper GJ. Simultaneous external subretinal fluid drainage and intravitreal gas injection in nonvitrectomized eyes with a special 27-gauge needle. *Arch Ophthalmol* 104:1394-1395, 1986.
22. Rabon RJ, Louis GJ, Zegarra H, Gutman FA. Acute bilateral posterior angiopathy with influenza A viral infection. *Am J Ophthalmol* 103:289-293, 1987.
23. McDonald HR, Abrams GW, Irvine AR, Sipperley JO, Boyden BS, Flore JV, Zegarra H. The management of subretinal gas following attempted pneumatic retinal reattachment. *Ophthalmology* 94:319-326, 1987.
24. McAllister IL, Zegarra H, Meyers SM, Gutman FA. Treatment of retinal detachments with multiple breaks by pneumatic retinopexy. *Arch Ophthalmol* 105:913-916, 1987.
25. Allen KM, Meyers SM, Zegarra H. Nanophthalmic uveal effusion. *Retina* 8:145-147, 1988.
26. McAllister IL, Meyers SM, Zegarra H, Gutman FA, Zakov ZN, Beck GJ. Comparison of pneumatic retinopexy with alternative surgical techniques. *Ophthalmology* 95:877-883, 1988.
27. Straatsma BR, Fine SL, Earle JD, Hawkins BS, Diener-West M, McLaughlin JA, Collaborative Ocular Melanoma Study Research Group. Enucleation versus plaque irradiation for choroidal melanoma. *Ophthalmology* 95:1000-1004, 1988.
28. Ambler JS, Meyers SM, Zegarra H, Gutman FA. The management of retinal detachment complicating degenerative retinoschisis. *Am J Ophthalmol* 107:171-176, 1989.
29. Ambler JS, Zegarra H, Meyers SM. Delayed reabsorption of subretinal fluid after pneumatic retinopexy (letter; comment on Chan CK, Wessels IF, Delayed reabsorption of subretinal fluid after pneumatic retinopexy. *Ophthalmology* 96:1691-1700, 1989). *Ophthalmology* 97:695 1990.

30. Ambler JS, Zegarra H, Meyers SM, Paranandi L. Reoperations and visual results after failed pneumatic retinopexy. *Ophthalmology* 97:786-790, 1990.
31. Ambler JS, Zegarra H, Meyers SM. Chronic macular detachment following otherwise successful pneumatic retinopexy. *Retina* 10:125-130, 1990.
32. Collaborative Ocular Melanoma Study Group. Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS Report No. 1. *Arch Ophthalmol* 108:1268-1273, 1990.
33. Marcus DM, Minkovitz JB, Wardwell SD, Albert DM for the Collaborative Ocular Melanoma Study Group. The value of nucleolar organizer regions in uveal melanoma. *Am J Ophthalmol* 110:527-534, 1990.
34. Vestal KP, Meyers SM, Zegarra H. Retinal detachment as a complication of retrobulbar anesthesia. *Can J Ophthalmology* 26:32-33, 1991.
35. Zegarra H. Summary and comment on: Sprafka JM, Frische TL, Baker R, Kurth D, Whipple D. Prevalence of undiagnosed eye disease in high-risk diabetic individuals. *Diabetes Spectrum* 4:163-164, 1991.
36. Fong ACO, Schatz H, McDonald HR, Burton TC, Maberley AL, Joffe L, Zegarra H, Nadel AJ, Johnson RN. Central retinal vein occlusion in young adults (papillophlebitis). *Retina* 12:3-11, 1992.
37. Collaborative Ocular Melanoma Study Group. Complications of enucleation surgery. COMS Report No. 2. In Franklin RM (ed). *Proceedings of the Symposium on Retina and Vitreous, New Orleans Academy of Ophthalmology*. New York: Kugler Publications, 1993, pp 181-190.
38. Collaborative Ocular Melanoma Study Group. Design and methods of a clinical trial for a rare condition: the Collaborative Ocular Melanoma Study. COMS Report No. 3. *Controlled Clin Trials* 14:362-391, 1993.
39. Central Vein Occlusion Study Group. Baseline and early natural history report: The Central Vein Occlusion Study (CVOS). *Arch Ophthalmol* 1993;111:1087-1095.
40. Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: The Central Vein Occlusion Study Group M Report. *Ophthalmology* 1995;102:1425-1433.
41. Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: The Central Vein Occlusion Study Group N Report. *Ophthalmology* 1995; 102:1434-1444.
42. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the

- treatment of postoperative bacterial endophthalmitis. *Arch Ophthalmol* 1995;113:1479-1496.
43. Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. *Arch Ophthalmol* 1997;115:486-91; erratum in *Arch Ophthalmol* 1997;115:1275.
  44. Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. *Arch Ophthalmol* 1997;115:865-872.
  45. The Collaborative Ocular Melanoma Study Group. Mortality in patients with small choroidal melanoma. COMS Report No. 4. *Arch Ophthalmol* 115:886-893, 1997.
  46. Grossniklaus HE, Albert DM, Green WR, Conway BP, Hovland KR for the Collaborative Ocular Melanoma Study Group. Clear cell differentiation in choroidal melanoma. COMS report no. 8. *Arch Ophthalmol* 115:894-898, 1997.
  47. The Collaborative Ocular Melanoma Study Group. Factors predictive of growth and treatment of small choroidal melanoma. COMS Report No. 5. *Arch Ophthalmol* 115:1537-1544, 1997.
  48. Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in eyes with large drusen. Short-term effects seen in a pilot randomized clinical trial. *Ophthalmology* 1998;105:11-23.
  49. The Collaborative Ocular Melanoma Study Group. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS Report No. 6. *Am J Ophthalmol* 125:745-766, 1998.
  50. The Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. I. Characteristics of patients enrolled and not enrolled. COMS Report No. 9. *Am J Ophthalmol* 125:767-778, 1998.
  51. The Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. II. Initial mortality findings. COMS Report No. 10. *Am J Ophthalmol* 125:779-796, 1998.
  52. Collaborative Ocular Melanoma Study Group: The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma III. Local complications and observations following enucleation. COMS Report No. 11. *Am J Ophthalmol* 126: 362-372, 1998.

53. Choroidal Neovascularization Prevention Trial Research Group. Choroidal neovascularization in the choroidal neovascularization prevention trial. *Ophthalmology* 1998;105:1364-1372.
54. Collaborative Ocular Melanoma Study Group. Echography (ultrasound) procedures for the Collaborative Ocular Melanoma Study. COMS Report No. 12. *J Ophth Nurs Technol* Part I 18:143-149, Part II 18:219-232, 1999.
55. COMS Quality of Life Study Group. Quality of life assessment in the collaborative ocular melanoma study: design and methods. COMS-QOLS Report No. 1. *Ophthalmic Epidemiol* 6:5-17, 1999.
56. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials—TAP Report 1. *Arch Ophthalmol* 1999;117:1329-1345.
57. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. TAP report #2. *Arch Ophthalmol* 2001;119:198-207.
58. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: One-year results of a randomized clinical trial. VIP report #1. *Ophthalmology* 2001;108:841-852.
59. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. Verteporfin in Photodynamic Therapy Report 2. *Am J Ophthalmol* 2001;131:541-560.
60. Doft BH, Wisniewski SR, Kelsey SF, Fitzgerald SG; Endophthalmitis Vitrectomy Study Group. Diabetes and postoperative endophthalmitis in the endophthalmitis vitrectomy study. *Arch Ophthalmol* 2001;119:650-656.
61. Moy CS, Albert DM, Diener-West M, McCaffrey LD, Scully RE, Willson JK; The Collaborative Ocular Melanoma Study Group, prepared by COMS Mortality Coding Committee. Cause-specific mortality coding. Methods in the Collaborative Ocular Melanoma Study. COMS Report No. 14. *Control Clin Trials* 22:248-262, 2001.
62. The Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS Report No. 15. *Arch Ophthalmol* 119:670-676, 2001.
63. The Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal

- melanoma. I. Visual acuity after 3 years. COMS Report No. 16. *Ophthalmology* 108:348-366, 2001.
64. Grostern RJ, Slusker Shternfeld I, Bacus SS, Gilchrist K, Zimbric ML, Albert DM; Collaborative Ocular Melanoma Study Group. Absence of type I estrogen receptors in choroidal melanoma: analysis of Collaborative Ocular Melanoma Study (COMS) eyes. *Am J Ophthalmol* 131:788-791, 2001.
  65. Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of 1-125 brachytherapy for choroidal melanoma, II: Characteristics of patients enrolled and not enrolled. COMS Report No. 17. *Arch Ophthalmol* 119:951-965, 2001.
  66. Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of 1-125 brachytherapy for choroidal melanoma, III. Initial mortality findings. COMS Report No. 18. *Arch Ophthalmol* 119:969-982, 2001.
  67. Collaborative Ocular Melanoma Study Group. Sociodemographic and clinical predictors of participation in two randomized trials: Findings from the Collaborative Ocular Melanoma Study. COMS Report No. 7. *Controlled Clin Trials* 22:526-537, 2001.
  68. Verteporfin Roundtable 2000 And 2001 Participants, Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators, and Verteporfin in Photodynamic Therapy (VIP) Study Group Principal Investigators Group. Guidelines for using verteporfin (Visudyne<sup>®</sup>) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. *Retina* 2002;22:6-18.
  69. Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman LJ, Slakter JS, Strong A, Vannier S, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Three-year results of an open-label extension of 2 randomized clinical trials – TAP report No. 5. *Arch Ophthalmol* 2002;120:1307-1314.
  70. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration. Additional information regarding baseline lesion composition's impact on vision outcomes – TAP Report No. 3. *Arch Ophthalmol* 2002;120:1443-1454.
  71. Rubin GS, Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Effects of verteporfin therapy on contrast sensitivity: results from the Treatment of Age-related macular degeneration with Photodynamic therapy (TAP) Investigation – TAP Report No. 4. *Retina* 2002;22:536-544.

72. Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS Report No. 19. *Ophthalmology* 109:2197-2206, 2002.
73. Straatsma BR, Diener-West M, Caldwell R, Engstrom RE; Collaborative Ocular Melanoma Study Group. Mortality after deferral of treatment or no treatment for choroidal melanoma. *Am J Ophthalmol* 136:47-54, 2003.
74. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger S, Luna S, Robertson SM, Russell S, Singerman L, Slakter JS, Sullivan EK, Yannuzzi L, Zilliox P; The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. *Retina* 2003;23:14-23.
75. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JJ, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA; Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial – VIP Report No. 3. *Ophthalmology* 2003;110:667-673.
76. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna SP, Robertson SM, Russell S, Singerman L, Slakter JS, Yannuzzi L, Zilliox P; Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. *Ophthalmology* 2003;110:2372-2383.
77. Melia M, Moy CS, Reynolds SM, Cella D, Murray TG, Hovland KR, Hayman JA, Mangione CM, the Collaborative Ocular Melanoma Study-Quality of Life Study Group. Development and validation of disease-specific measures for choroidal melanoma: COMS-QOLS report No. 2. *Arch Ophthalmol* 121:1010-1020, 2003.
78. Collaborative Ocular Melanoma Study Group. Trends in size and treatment of recently diagnosed choroidal melanoma, 1987-1997: findings from patients examined at collaborative ocular melanoma study (COMS) centers: COMS Report No. 20. *Arch Ophthalmol* 121:1156-1162, 2003.
79. Collaborative Ocular Melanoma Study Group. Comparison of clinical, echographic, and histopathological measurements from eyes with medium-sized choroidal melanoma in the collaborative ocular melanoma study: COMS Report No. 21. *Arch Ophthalmol* 121:1163-1171, 2003.
80. Azab M, Benchaboune M, Blinder KJ, et al; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group; Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety

- results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. *Retina* 2004;24:1-12.
81. Complications of Age-related Macular Degeneration Prevention Trial Study Group. The Complications of Age-related Macular Degeneration Prevention Trial (CAPT): rationale, design, and methodology. *Clinical Trials* 2004; 1:91-107.
  82. Bressler SB, Pieramici DJ, Koester JM, Bressler NM for the TAP Study Group. Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to management – TAP report No. 6. *Arch Ophthalmol* 2004 Mar;122:325-329.
  83. Collaborative Ocular Melanoma Study Group. Ten-year follow-up of fellow eyes of patients enrolled in Collaborative Ocular Melanoma Study (COMS) randomized trials. COMS Report No. 22. *Ophthalmology* 111:966-976, 2004.
  84. Maguire M; Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). *Ophthalmology* 2004;111:1307-1316.
  85. Hawkins BS, Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. *Am J Ophthalmol* 2004;138:936-951.
  86. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med* 2004 Dec 30;351:2805-2816.
  87. PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the protein kinase C {beta} inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial. *Diabetes* 2005; 54:2188-2197.
  88. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. *N Engl J Med* 355:1432-1444, 2006.
  89. Complications of Age-related Macular Degeneration Prevention Trial Research Group. Laser treatment in patients with bilateral large drusen: The Complications of Age-Related Macular Degeneration Prevention Trial. *Ophthalmology* 113:1974-1986, 2006.

90. Russell SR, Hudson HL, Jerdan JA; Anecortave Acetate Clinical Study Group. Anecortave acetate for the treatment of exudative age-related macular degeneration--a review of clinical outcomes. *Surv Ophthalmol* 2007;52 Suppl 1:S79-90.
91. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreal dexamethasone drug delivery system in patients with persistent macular edema. *Arch Ophthalmol* 2007;125:309-317.
92. Rosenfeld PJ, Boyer DS, Bressler NM, Fish G, Grizzard WS, Hao Y, Hnik P, Hudson HL, Singerman L, Slakter JS; VALIO Study Group. Verteporfin therapy of subfoveal occult choroidal neovascularization in AMD using delayed light application: one-year results of the VALIO Study. *Am J Ophthalmol* 2007;144:970-972.
93. Macugen AMD Study Group, Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. *Ophthalmology* 2007;114:1702-1712.
94. Maguire MG, Alexander J, Fine SL; Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group. Characteristics of choroidal neovascularization in the complications of age-related macular degeneration prevention trial. *Ophthalmology* 2008;115:1468-1473, 1473.e1-2. Epub 2008 May 16.
95. Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group. Risk factors for choroidal neovascularization and geographic atrophy in the complications of age-related macular degeneration prevention trial. *Ophthalmology* 2008;115:1474-1479, 1479.e1-6. Epub 2008 May 27.
96. Ying G-S, Maguire M, Liu C, Antoszyk A, Complications of Age-related Macular Degeneration Prevention Trial Research Group. Night vision symptoms and progression of age-related macular degeneration (AMD) in the Complications of AMD Prevention Trial. *Ophthalmology*. Epub 2008 Jul 30.
97. Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa M, Harrington MW; Macular Telangiectasia Research Group. The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project. *Invest Ophthalmol Vis Sci* 2008;49:4340-4346.
98. Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Figueroa M, Antoszyk A, Elman M and the SCORE Study Investigator Group. SCORE Study Report 3: Study design and baseline characteristics. *Ophthalmology* 2009;116:1770-1777.
99. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. *Arch Ophthalmol* 2009;127:1101-1114.

100. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. *Arch Ophthalmol* 2009;127:1115-1128.
101. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. *N Engl J Med*. 2011 May 19;364:1897-1908. Epub 2011 Apr 28.
102. Coney JM, Zegarra H, Zakov ZN. Treatment of serous retinal detachments in optic nerve head pits with periocular steroids and carbonic anhydrase inhibitors: case studies (*in preparation*).
103. Coney JM, Zegarra H, Zakov ZN. The efficacy of binocular indirect laser in the treatment of ischemic central retinal vein occlusions (*in preparation*).
104. Coney JM, Zegarra H, Zakov ZN. Prophylactic binocular indirect laser for the prevention of recurrent retinal detachments in scleral buckle removal (*in preparation*).

### **Book Chapters**

1. Gutman FA, Zegarra H, Zakov ZN. Temporal retinal branch vein occlusion: correlation of fluorescein angiography and visual prognosis. In Cant JS (ed): *Vision and Circulation*. London, Henry Kimpton, 1976, p 43.
2. Tomsak RL, Zegarra H, Gutman FA. Bilateral central scotomas from macular ischemia. In Smith JL (ed). *Neuro-ophthalmology Focus – 1982*. New York, Masson, 1982, pp 99-104.
3. Zegarra H, Meyers SM, McAllister I. Clinical experience: Cleveland, Ohio. In Tornambe PE, Grizzard WS (eds). *Pneumatic Retinopexy: A Clinical Symposium*. Chicago, Greenwood Publishing, 1989, pp 142-147.
4. Zegarra H, Ambler JS, Meyers SM. Reoperations for pneumatic retinopexy failures. In Tornambe PE, Grizzard WS (eds). *Pneumatic Retinopexy: A Clinical Symposium*. Chicago, Greenwood Publishing, 1989, pp 102-107.
5. Singerman LJ, Addiego R, Lamkin JC, Zegarra H. Laser therapy for choroidal neovascularization. In Karlin DB (ed). *Lasers in Ophthalmology*. Cambridge, Mass: Blackwell Scientific Publications, Inc, 1995.
6. Singerman LJ, Addiego R, Lamkin JC, Zegarra H. Laser therapy for other macular diseases. In Karlin DB (ed). *Lasers in Ophthalmology*. Cambridge, Mass: Blackwell Scientific Publications, Inc, 1995.
7. Zegarra H, Finkelstein D, Singerman LJ, Niffenegger JH. Laser management of branch and central retinal vein occlusions. In Singerman LJ, Coscas G (eds). *Current*

*Techniques in Ophthalmic Laser Surgery*. Philadelphia: Current Medicine, 1999, pp 67-76.

8. Zegarra H, Singerman LJ, Pendergast SD. Central retinal vein occlusion. In Saer JB (ed.). *Vitreo-Retinal and Uveitis Update. Proceedings of the New Orleans Academy of Ophthalmology Symposium*. The Hague: Kugler Publications 1998, pp 259-267.
9. Pendergast SD, Singerman LJ, Niffenegger JH, Zegarra H. Laser treatment for proliferative diabetic retinopathy. In Saer JB (ed.). *Vitreo-Retinal and Uveitis Update. Proceedings of the New Orleans Academy of Ophthalmology Symposium*. The Hague: Kugler Publications, 1998.

### **Posters**

1. Ludwig I, Zegarra H, Zakov ZN. The acute retinal necrosis syndrome. Herpes simplex retinitis? Poster, American Academy of Ophthalmology Annual Meeting, Chicago, Illinois, October 30 to November 3, 1983.
2. Albanese U, Zegarra H, Zakov ZN. Xenon endophotocoagulation and neovascular glaucoma in postvitrectomy diabetic eyes. Poster, Association for Research in Vision and Ophthalmology Annual Meeting, Sarasota, Florida, May 2-5, 1983; Pan American Congress of Ophthalmology, Lima, Peru, July 3-8, 1983.
3. Gutman FA, Zegarra H, Zakov ZN, Ross D. Poster, International Congress of Ophthalmology, San Francisco, California, November 1-2, 1984.
4. Cole L, Zakov ZN, Haik B, Meisler DM, Zegarra H, Berlin J, Berlin L, Ellsworth R, Chang S. Poster, The varied presentation of cutaneous malignant melanoma metastatic to the eye and orbit. American Academy of Ophthalmology Annual Meeting, San Francisco, California, September 29 to October 3, 1985.
5. Sharma MC, Miller DG, Zakov ZN, Pendergast SD, Novak MA, Zegarra H, Singerman LJ. Results of the surgical management of idiopathic epiretinal membrane. Scientific Poster 472, American Academy of Ophthalmology Annual Meeting, October 2005.